RxDoctor Payments Data

Diahann Wilcox, APRN

Nurse Practitioner · Farmington, CTNPI 1417954249

Payments from drug & device makers

$941in general payments, 2019–2025

Across 15 payments — averaging $62.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$238
  • Verona Pharma, Inc.$154
  • United Therapeutics Corporation$129
  • Regeneron Healthcare Solutions, Inc.$125
  • Avadel CNS Pharmaceuticals, LLC$119
  • AstraZeneca$101
  • plus $74 from 2 others

What the payments were for

  • Consulting fees$20021%
  • Food & beverage$71776%
  • Education$243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$28,476
Medicare patients
154
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag24$794,731
AdempasRiociguat33$581,025
Tyvaso DpiTreprostinil20$468,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter385$381,587
OpsumitMacitentan12$153,841
Ambrisentan37$149,768
Dupixent PenDupilumab30$110,745
Breo ElliptaFluticasone/Vilanterol159$94,148
Tadalafil65$85,255
Dupixent SyringeDupilumab13$79,314
AdcircaTadalafil14$56,773
Spiriva RespimatTiotropium Bromide51$53,376
XolairOmalizumab15$51,782
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$48,812
Incruse ElliptaUmeclidinium Bromide42$25,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$14$948,57236 claims
BayerAdempas$238$581,02533 claims
United Therapeutics CorporationAdcirca$129$56,77314 claims
AstraZenecaBreztri Aerosphere, Symbicort$101$35,10453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →